Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Neridronic acid is an amino bisphosphonate that inhibits farnesyl pyrophosphate (FPP) synthase (IC50 = 388.2 nM in a cell-free assay).1 It decreases the differentiation of RAW 264.7 cells into osteoclasts in a CRL-12257 co-culture model of osteoclastogenesis when used at concentrations ranging from 0.001 to 100 µM.2 Neridronic acid (30 µM) inhibits FGF2-induced proliferation and tube formation in human umbilical vein endothelial cells (HUVECs).3 It reduces the loss of trabeculae and increases bone density in the tibial metaphysis of growing rats when administered subcutaneously at a dose of 0.1 mg/kg per day.4
WARNING This product is not for human or veterinary use.
1. Structure-
2. Effects of neridronic acid on osteoclasts derived by physiological dual-
3. Neridronate inhibits angiogenesis in vitro and in vivo. Clin. Rheumatol. 26(7), 1094-1098 (2007).
4. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 38(6), 342-349 (1986).